According to a new report, published by KBV research, The Global Oncology Drugs Market size is expected to reach $273.3 billion by 2030, rising at a market growth of 7.7% CAGR during the forecast period.
The Breast Cancer segment is leading the Global Oncology Drugs Market by Indication in 2022, thereby, achieving a market value of $44 billion by 2030. Due to increase in number of females suffering from breast cancer. In addition, the adoption of unhealthy lifestyles, increasing female geriatric population, vulnerability to harmful radiation, and growing governmental initiatives also contributed toward the growth of the market. Individualized treatment plans, multidisciplinary care, and patient involvement in decision-making are essential elements of the comprehensive approach to managing breast cancer.
The Chemotherapy segment would experience a CAGR of 8.7% during (2023 - 2030). Chemotherapy is designed to target and kill rapidly dividing cancer cells. This can significantly reduce the size of tumors, helping to control or eliminate cancer in some cases. Tumor shrinkage can be crucial for improving symptoms, preventing the spread of cancer, and facilitating surgical interventions. In many cases, chemotherapy contributes to improved long-term survival rates. Advances in chemotherapy regimens and the development of targeted therapies have led to increased efficacy and better outcomes for some cancer patients.
The North America region dominated the Global Oncology Drugs Market by Region in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $100 billion by 2030. The Europe region is anticipated a CAGR of 7.5% during (2023 - 2030). Additionally, The Asia Pacific region is poised to grow a CAGR of 8.5% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/oncology-drugs-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AbbVie, Inc., Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc. and Pfizer Inc.
By Indication
By Drug Class Type
By Geography
Companies Profiled
Unique Offerings 
